How to buy Nuvalent stock (Nuvalent)

Nuvalent is a biotechnology business based in the US. Nuvalent shares (NUVL) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $83.85 – a decrease of 4.82% over the previous week. Nuvalent employs 127 staff and has a market cap (total outstanding shares value) of 0.00.

Our top picks for where to buy Nuvalent stock

Buy Nuvalent stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Nuvalent stock price (NASDAQ: NUVL)

Use our graph to track the performance of NUVL stocks over time.

Nuvalent shares at a glance

• Key figures

Information last updated 2024-12-18.

Latest market close	$83.85
52-week range	$61.80 - $113.51
50-day moving average more info button	$94.42
200-day moving average more info button	$82.42
Wall St. target price	$115.50
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$-3.49

Is it a good time to buy Nuvalent stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Nuvalent price performance over time

Historical closes compared with the close of $84.22 from 2024-12-20

1 week (2024-12-17)	-4.40%
1 month (2024-11-22)	-11.28%
3 months (2024-09-24)	-16.86%
6 months (2024-06-24)	4.47%

1 year (2023-12-22)	15.18%
2 years (2022-12-23)	196.13%
3 years (2021-12-23)	338.19%
5 years (2019-12-20)	N/A

Nuvalent financials

Gross profit TTM	$0
Return on assets TTM	-18.63%
Return on equity TTM	-29.57%
Profit margin	0%
Book value	$15.81
Market Capitalization more info button	$5.9 billion

TTM: trailing 12 months

Nuvalent share dividends

We're not expecting Nuvalent to pay a dividend over the next 12 months.

You may also wish to consider:

Nuvalent share price volatility

Over the last 12 months, Nuvalent's shares have ranged in value from as little as $61.795 up to $113.51. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Nuvalent's is 1.328. This would suggest that Nuvalent's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

To put Nuvalent's beta into context you can compare it against those of similar companies.

• Charles River Laboratories (CRL.US): 1.376
• Recursion Pharmaceuticals (RXRX.US): 0.802
• BioLife Solutions (BLFS.US): 1.883

Nuvalent overview

Nuvalent, Inc. , a clinical stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the phase 2 portion of the ALKOVE-1 Phase 1/2 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR, which is expected to initiate phase 1 trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts. .

Frequently asked questions

What percentage of Nuvalent is owned by insiders or institutions?
Currently 2.839% of Nuvalent shares are held by insiders and 108.457% by institutions. How many people work for Nuvalent?
Latest data suggests 127 work at Nuvalent. When does the fiscal year end for Nuvalent?
Nuvalent's fiscal year ends in December. Where is Nuvalent based?
Nuvalent's address is: One Broadway, Cambridge, MA, United States, 02142 What is Nuvalent's ISIN number?
Nuvalent's international securities identification number is: US6707031075